Home

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the US Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease (PAD) indication for the Xarelto(rivaroxaban) vascular dose (2.5mg twice daily plus aspirin 100mg once daily) to include patients following recent lower-extremity revascularisation (LER) due to symptomatic PAD.

The approval is based on data from the Phase III VOYAGER PAD study. According to a press release, Xarelto is now the first and only therapy indicated to help reduce the risks of major cardiovascular events in patients with coronary artery disease (CAD) and major thrombotic vascular events, such as myocardial infarction, ischaemic stroke, acute limb ischaemia, and major amputation of a vascular aetiology, in patients with PAD, including patients who have recently undergone LER due to symptomatic PAD.

“For more than 20 years, many physicians have used dual antiplatelet therapy after lower extremity revascularisation due to symptomatic PAD with limited data to support efficacy and safety in this setting. Now, the VOYAGER PAD and COMPASS clinical studies have demonstrated the utility of dual pathway inhibition in targeting both platelets and thrombin in patients with PAD. These data provide a new mechanism of treatment using an evidence-based strategy for this vulnerable population,” said Marc P Bonaca (University of Colorado Anschutz Medical Campus, Aurora, USA). “This FDA approval of rivaroxaban plus aspirin is a major advancement for PAD management and sets the stage to evolve the current standard of care for patients with PAD.”

Xarelto now has nine indications in the USA. Today’s approval is based on the Phase III VOYAGER PAD trial, which demonstrated the Xarelto vascular dose (2.5mg twice daily plus aspirin 100mg once daily) reduced the risk of major adverse limb and cardiovascular events by 15% in patients with symptomatic PAD post-LER compared to aspirin alone.The VOYAGER PAD trial saw no significant difference in Thrombolysis in Myocardial Infarction (TIMI) major bleeding between Xarelto with aspirin compared to aspirin alone.

The results from the VOYAGER PAD study complement findings from the landmark Phase III COMPASS trial, which also examined the dual pathway approach of Xarelto with aspirin in CAD and/or PAD patients and further supports this FDA label extension in PAD patients. Data from the Phase III COMPASS trial resulted in FDA approval in 2018 to reduce the risk of major cardiovascular events, such as heart attack, stroke and cardiovascular death in people with chronic PAD and CAD. While there were more major bleeds with the Xarelto vascular dose in COMPASS, there was no significant difference in rates of fatal bleeding, intracranial bleeding or symptomatic bleeding into a critical organ.

Source VascularNews

Duc Tin CLinic

Chia sẽ qua facebook bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua google bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua twitter bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua MySpace bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua LinkedIn bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua stumbleupon bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua icio bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua digg bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Chia sẽ qua yahoo bài: FDA approves expanded PAD indication for Xarelto plus aspirin

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.